The U.S. based Abbvie’s investigational drug, ABT-493 and ABT-530 with Ribavirin (RBV) demonstrated sustained virologic response (SVR12) in 91% of chronic genotype 1 hepatitis C virus infected patients in 12 weeks of the primary intent-to-treat analysis. It is noteworthy that these patients had failed previous therapy with direct acting antivirals.

Apparently MAGELLAN-1 is a Phase II study of evaluation of the efficiency and safety of ABT-493 and ABT-530 with and without RBV in adults with GTI HCV on a random basis. The study followed the following approach; In the part I of the study, 50 patients with GTI but without cirrhosis were randomly selected to receive once daily ABT-493 and ABT-530 at doses 200/80 mg, 300/120mg with 800 mg RBV or 300/120 mg without RBV for 12 weeks. These were those patients who had earlier failed the therapy containing protease inhibitor and / or NS5A inhibitor. First six patients of the once daily ABT-493 at 206/80 mg showed 100% achievement of SVR12. For More Information, Visit Us http://medgenera.com/